Neurofibromatosis 2
Pipeline by Development Stage
Drug Modality Breakdown
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 38 trials with date data
Clinical Trials (39)
Total enrollment: 4,492 patients across 39 trials
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled Study
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.
Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec
PTC299 for Treatment of Neurofibromatosis Type 2
Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours
International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia
A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers
A Study of Selumetinib in Patients With Kaposi's Sarcoma
Selumetinib Paediatric NF1 Japan Study
A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants
Selumetinib and Olaparib in Solid Tumors
Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers
A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy Subjects
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in Volunteers
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
ABC-04 a Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer
A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
Real-World Treatment Study of Koselugo (Selumetinib)
Non-interventional Study of Patients With PN NF1 Starting Selumetinib in Russia
PASS of Paediatric Patients Initiating Selumetinib